Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
K. Schoonjans, J. Auwerx.
Thiazolidinediones: an update.
Lancet, 355 (2000), pp. 1008-1010
[2.]
G. Martin, H. Duez, C. Blanquart, V. Berezowski, P. Poulain, J.C. Fruchart, et al.
Statin-induced inhibition of the Rho-signaling pathway activates PPARa and induces HDL apoA-I.
J Clin Invest, 107 (2001), pp. 1423-1432
[3.]
S.M. Haffner, A.S. Greenberg, W.M. Weston, H. Chen, K. Williams, M.I. Freed.
Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
Circulation, 106 (2002), pp. 679-684
[4.]
J. Girona, A.E. La Ville, R. Solà, N. Plana, L. Masana.
Simvastatin decreases aldehyde production derived from lipoprotein oxidation.
Am J Cardiol, 83 (1999), pp. 846-851
[5.]
J.F. Whitfield, P. Morley, G.E. Willick.
The control of bone growth by parathyroid hormone, leptin, & statins.
Crit Rev Eukaryot Gene Expr, 12 (2002), pp. 23-51
[6.]
G. Llaverías, D. Lacasa, M. Alegret.
Efectos de la combinación rosiglitazona- atorvastatina sobre la expresión de genes implicados en la captación y en la salida de colesterol en el macrófago.
Clin Invest Arterioscler, 16 (2004), pp. 10-17
[7.]
A.A. Alsheikh, H.M. Abourjaily, R.H. Karas.
Risk of adverse events with concomitant use of atorvastatin or simvastatin and glucoselowering drugs (thiazolidinediones, metformin, sulfonylurea, insulin, and acarbose.
Am J Cardiol, 89 (2002), pp. 1308-1310
[8.]
M.I. Freed, R. Ratner, S.M. Marcovina, M.M. Kreider, N. Biswas, B.R. Cohen, et al.
on behalf of the Rosiglitazone Study 108 Investigators. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus.
Am J Cardiol, 90 (2002), pp. 947-952
[9.]
K.J. Moore, E.D. Rosen, M.L. Fitzgerald, F. Randow, L.P. Andersson, D. Altshuler, et al.
The role of PPAR-g in macrophage differentiation and cholesterol uptake.
Nat Med, 7 (2001), pp. 41-47
[10.]
H. Vosper, L. Patel, T.L. Graham, et al.
The peroxisome proliferatoractivated receptor delta promotes lipid accumulation in human macrophages.
J Biol Chem, 276 (2001), pp. 44258-44265
[11.]
G. Llaverías, M. Jové, M. Vázquez-Carrera, R. Sánchez, C. Díaz, G. Hernández, et al.
Avasimide and atorvastatin synergistically reduce cholesteryl ester content in THP-1 macrophages.
Eur J Pharmacol, 451 (2002), pp. 11-17
[12.]
S.C. Whitman, D.L. Rateri, S.J. Szilvassy, J.A. Cornicelli, A. Daugherty.
Macrophage-specific expression of class A scavenger receptors in LDL receptor(-/-) mice decreases atherosclerosis and changes spleen morphology.
J Lipid Res, 43 (2002), pp. 1201-1208
[13.]
Tontonoz, L. Nagy, J.G. Álvarez, V.A. Thomazy, R.M. Evans.
Ppargamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL.
Cell, 93 (1998), pp. 241-252
[14.]
J.C. Vallvé, K. Uliaque, J. Girona, A. Cabré, J. Ribalta, M. Heras, et al.
Unsaturated fatty acids and their oxidation products stimulate CD36 gene expression in human macrophages.
Atherosclerosis, 164 (2002), pp. 45-56
[15.]
L. Svensson, G. Camejo, A. Cabré, J.C. Vallvé, J. Pedreño, K. Norén, et al.
Fatty acids modulate the effect of darglitazone on macrophage CD36 expression.
Eur J Clin Invest, 33 (2003), pp. 464-471
[16.]
G. Chinetti, S. Lestavel, V. Bocher, A.T. Remaley, B. Neve, I. Pineda Torra, et al.
Ppara and Pparg activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway.
Nat Med, 7 (2001), pp. 53-58
Copyright © 2003. Sociedad Española de Arteriosclerosis y Elsevier España, S.L.